Effects of celecoxib combined with IMRT on immune function and serum tumor markers in elderly patients with advanced non-small cell lung cancer

Abstract

Abstract: Objective To analyze the effect of intensity modulated radiation therapy IMRT(intensity modulated radiation therapy) combined with celecoxib on immune function and serum tumor markers in patients with non-small cell lung cancer(NSCLC). Methods Sixty-two patients with NSCLC in Taihe County People's Hospital from January 2017 to December 2019 were selected and randomly divided into two groups; thirty patients with radiotherapy alone were set as the control group, and thirty-two patients with IMRT combined with celecoxib were set as the experimental group. Fasting venous blood was collected before and 4 weeks after treatment to detect the serum tumor markers, including carbohydrate antigen 50(CA50), carbohydrate antigen 125(CA125), carcinoma-embryonic antigen(CEA), squamous cell carcinoma associated antigen(SccAg) and T lymphocyte subsets(CD3⁺, CD4⁺, CD8⁺) in the two groups. The short-term efficacy of the two groups was evaluated, and the survival curve was drawn by Kaplan Meier. Results The total effective rate of the experimental group was 54.55%, which was significantly higher than that of the control group(31.82%)(P＜0.05); after treatment, the serum CA50, CA125, CEA, SCCAg levels of the two groups were significantly lower than those before treatment(P＜0.05), and the experimental group was significantly lower than that of the control group(P＜0.05); after treatment, the test value of CD3⁺, CD4⁺ in the experimental group was significantly higher than those before treatment(P＜0.05), and the value of CD8⁺ was significantly higher than those before treatment. Counting of CD3⁺ and CD4⁺ in the control group was significantly lower than that before treatment(P＜0.05), but CD8⁺ counting was significantly higher than at before treatment(P＜0.05). There was significant difference in T lymphocyte subsets between the two groups(P＜0.05). The 3-year survival rate of the experimental group was 38.64%, which was significantly higher than that of the control group(18.18%)(P＜0.05). Conclusions Intensity modulated radiation therapy combined with celecoxib in the treatment of elderly patients with advanced NSCLC significantly reduces the level of serum tumor markers, effectively enhances the immune function, and significantly improves the treatment outcome as well as enhances survival rate.

Key words: intensity modulated radiation therapy, non-small cell lung cancer, immune function, serum tumor markers, survival rate

CLC Number:

R734.2

REN Meng-xian, LIANG Wei, LIU Yan. Effects of celecoxib combined with IMRT on immune function and serum tumor markers in elderly patients with advanced non-small cell lung cancer[J]. Basic & Clinical Medicine, 2021, 41(6): 890-894.

References

[1] Herbst R, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer[J]. Nature,2018,553:446-454.
[2] 刘治超. 单/双药同步放化疗治疗老年局部晚期非小细胞肺癌患者的对比研究[D]. 济南:济南大学,2018:23-27.
[3] 徐丹,王于理,李晶,等. T790 M及COX-2在晚期非小细胞肺癌EGFR-TKI耐药中的临床研究[J]. 广州医药,2019,50:57-61.
[4] 王湘萍,湛永滋,毛艳,等. 塞来昔布对鼻咽癌放化疗增敏的作用[J]. 中国癌症防治杂志,2018,10:393-396.
[5] 张贺龙. 实体瘤疗效评价标准及演变[J]. 现代肿瘤医学,2010,18:839-841.
[6] 张英,李杨. 局部晚期非小细胞肺癌放化疗预后及相关影响因素分析[J]. 内蒙古医学杂志,2020,52:774-776.
[7] 孙立越. NSCLC放射敏感性与EGFR基因突变的相关性及机制研究[D]. 广州:广东药科大学,2017:13-17.
[8] 李三科,洪振宇,苗战会,等. GW5074抑制高剂量小范围放射线诱导的肺泡上皮细胞间质转化[J]. 南京医科大学学报(自然科学版),2019,39:1555-1560.
[9] Gulyas M, Mattsson J, Lindgren A, et al. COX-2 expression and effects of celecoxib in addition to standard chemotherapy in advanced non-small cell lung cancer[J]. Acta Oncol,2018,57:244-250.
[10] Bommu D, Konidala K, Pamanji R, et al. Structural probing, screening and structure-based drug repositioning insights into the identification of potential cox-2 inhibitors from selective coxibs[J]. Interdiscip Sci,2019,11:153-169.
[11] 任晓晓,张小茜,张红梅,等. 塞来昔布联合FOLFOX4方案治疗晚期胃癌的疗效及机制研究[J]. 中国现代医学杂志,2018,28:27-31.
[12] 雷新军,涂建飞,王慧梅,等. 多模态CT检查联合肿瘤标志物评估塞来昔布联合调强放疗对晚期非小细胞肺癌的疗效[J]. 中国慢性病预防与控制,2018,26:936-938.
[13] Bernard A, Georg E, Dennis G, et al. Tumor infiltrating T cells influence prognosis in stage I-III non-small cell lung cancer.[J]. Thorac Dis,2020,12:1824-1842.
[14] 王雅静,施润,游庆军,等. 塞来昔布对手术应激产生的非小细胞肺癌抗失巢凋亡的影响[J]. 中华实验外科杂志,2018,35:695-698.

[1]	ZHENG Hong, CHEN Xiaoxia, HAN Lizhou, CHEN Miao, HUANGFU Juan. Decrease of lncRNA-RMRP expression inhibits proliferation and invasion of human lung cancer cell line A549 [J]. Basic & Clinical Medicine, 2024, 44(7): 974-978.
[2]	LIANG Xiangcun, WEI Xiaoyu, LIANG Jian, WANG Qing, GENG Guang. Anlotinib inhibits proliferation and promotes apoptosis of human non-small cell lung cancer cell lines through miR-16-5p/PD-1 axis [J]. Basic & Clinical Medicine, 2024, 44(4): 503-512.
[3]	ZHANG Jing, YANG Zigeng, CAI Wenqin, CAO Weiwei, WEI Hongmei, XUE Xixi, WU Bin. Inhibition of prohibitin 2 enhances the sensitivity of non-small cell lung cancer cell line A549 to erlotinib [J]. Basic & Clinical Medicine, 2024, 44(3): 325-332.
[4]	LI Juan, LI Xiaofeng, XU Shengzhi, TANG Kai. Efficacy of cinobufacini capsule combined with docetaxel plus cisplatin chemotherapy for the treatment of non-small cell lung cancer [J]. Basic & Clinical Medicine, 2024, 44(2): 247-251.
[5]	DING Fei, WANG Sa, HUANG Changxin. Serum CA211 level and NK cell number are associated with prognosis of patients with non-small cell lung cancer [J]. Basic & Clinical Medicine, 2024, 44(2): 180-184.
[6]	. Association of seven antibody levels in lung cancer with chemotherapy effect and prognosis in patients with NSCLC [J]. Basic & Clinical Medicine, 2024, 44(10): 1383-1387.
[7]	YAN Chenhong, JIN Er. Progress of exosomal PD-L1 in diagnosis and treatment of non-small cell lung cancer [J]. Basic & Clinical Medicine, 2023, 43(9): 1457-1461.
[8]	ZHANG Xiaowan, KANG Xia, YAO Xiaoying, XIE Fang, LI Ying. Silencing SF3B1 promotes apoptosis and inhibits proliferation and invasion of human lung cancer cell line A549 [J]. Basic & Clinical Medicine, 2023, 43(8): 1265-1270.
[9]	ZHANG Jing, YANG Zigeng, WEI Hongmei, NING Haihong, XUE Xixi, JIN Ling, WU Bin. Knockdown of prohibitin 2 promotes apoptosis in non-small cell lung cancer cell line A549 [J]. Basic & Clinical Medicine, 2023, 43(10): 1522-1529.
[10]	HE Shao-bo, LUO Fu-hua, JIANG Chuan-ming, LIU Xuan-mei. Salidroside inhibits the proliferation and epithelial mesenchymal transformation of NSCLC cell by negatively regulation of TACC2 expression [J]. Basic & Clinical Medicine, 2022, 42(11): 1681-1689.
[11]	JIANG Xue-dong, LI Wen-ya. Erastin induces cell apoptosis in human non-small cell lung cancer cell line A549 [J]. Basic & Clinical Medicine, 2021, 41(9): 1313-1317.
[12]	WAN Xue-qiong, CHEN Jia, HE Chao, YE Xing-ming. Zerumbone inhibits the proliferation, migration and invasion of human non-small cell lung cancer cell line A549 through up-regulating FBXW7 expression [J]. Basic & Clinical Medicine, 2021, 41(8): 1163-1168.
[13]	LIU Xi-bang, ZHU Lin-zhi, JIAO De-min, TANG Xia-li, CHEN Jun, HU Xu-gang, CHEN Qing-yong. Anlotinib combined with chloroquine induces apoptosis of human non-small cell lung cancer cell line H1299 [J]. Basic & Clinical Medicine, 2021, 41(7): 1018-1023.
[14]	HAN Yan, GUAN Bing-qi, ZHOU Gang, MA Fei. Predictive value of Xiaoyan decoction combined with GC chemotherapy in the treatment of advanced non-small cell lung cancer based on DWI [J]. Basic & Clinical Medicine, 2021, 41(5): 661-666.
[15]	LIU Qian, TANG Jian-hua, ZHANG Zhi-hua. Triptolide inhibits the proliferation and promotes apoptosis of non-small cell lung cancer cell line A549 [J]. Basic & Clinical Medicine, 2020, 40(3): 315-320.